Abstract
Dulaglutide (Trulicity—Eli Lilly), a glucagonlike peptide (GLP-1) receptor agonist, is the third once-weekly injection to be approved by FDA as an adjunct to diet and exercise in adults with type 2 diabetes. Exenatide extended-release (Bydureon—Astra Zeneca) and albiglutide (Tanzeum—GlaxoSmothKline) are already on the market, with the approval of dulaglutide offering clinicians another treatment option after initial antidiabetic treatment strategies, such as diet and lifestyle modifications and metformin, fail.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
